logo

For the Inventor, By the Inventor

Palo Alto, CA, United States of America

Riboscience LLC

Calculating rank
USPTO Granted Patents = 12

% Expired Patents = 16.7



Forward Citations = 18

Loading Chart...
Loading Chart...

6 inventors (with patents filed for the assignee):

goldMedal Klaus G Klumpp (10 out of 12 patents)

silverMedal Mark Smith (10 out of 52 patents)

bronzeMedal Zhuming Zhang (2 out of 29 patents)

4.  Jing Zhang (2 out of 15 patents)

5.  Francisco Xavier Talamas (1 out of 32 patents)

6.  Ronald Hawley (1 out of 1 patent)

7.  David Bernard Smith (89 patents)

8.  Klaus Klumpp (1 patent)

9.  Jing Zhang (0 patent)

10.  Joseph Armstrong Martin (0 patent)

11.  Christopher Mcguigan (0 patent)


12 patents:

1. 12029744 - Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors (2024-07-09),
2. 11351186 - 4'-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication (2022-06-07),
3. 10953030 - 4'-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication (2021-03-23),
4. 10682369 - 4'-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication (2020-06-16),
5. 10358458 - 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication (2019-07-23),
6. 10092649 - 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication (2018-10-09),
7. 9895442 - 4'-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication (2018-02-20),
8. 9708357 - 4'-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication (2017-07-18),
9. 9694028 - 4'-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication (2017-07-04),
10. 9370569 - 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication (2016-06-21),
11. 9249176 - 4'-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication (2016-02-02),
12. 9108999 - 2', 4′-difluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication (2015-08-18),
Company Overview
Riboscience LLC, based in Palo Alto, CA, specializes in the development of innovative RNA-targeted therapeutics. The company focuses on harnessing the potential of ribonucleic acid (RNA) to create novel treatment modalities for various diseases, leveraging advanced biotechnological approaches. Riboscience is committed to advancing the understanding of RNA biology and its applications in medicine, positioning itself at the forefront of the biotechnology sector with a strong emphasis on research and development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

12 Patents

#147 in Palo Alto, CA

#6,069 in California

#25,589 in US

#48,235 in the World

Palo Alto, CA (US)
Palo Alto, CA, United States of America

Riboscience LLC

Forward Citations = 18

6 inventors:

goldMedal Klaus G Klumpp (10 out of 12 patents)

silverMedal Mark Smith (10 out of 52 patents)

bronzeMedal Zhuming Zhang (2 out of 29 patents)

4.  Jing Zhang (2 out of 15 patents)

5.  Francisco Xavier Talamas (1 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Riboscience LLC. Retrieved from https://idiyas.com/company/riboscience

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…